SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients.

BMC Cancer · 2018 · PMC5921972 · PMID 29703253

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Of note, the two patients with KRAS amplification showed a trend of shorter PFS (53 days and 99 days, respectively) with no response to EGFR blockade, in accordance with the results described by a previous study [ 28 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.